News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Oct 20, 2021 7:15 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Oct 07, 2021
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
Sep 17, 2021
Forma Therapeutics to Participate in Upcoming Investor Conferences
Aug 13, 2021
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Upcoming Events
Sep 27, 2021
10:40 AM EDT
Cantor Global Healthcare Conference
Learn more
Sep 22, 2021
12:25 PM EDT
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Learn more
Aug 13, 2021
8:00 AM EDT
Forma Therapeutics Second Quarter 2021 Financial Results and Business Update
Learn more